CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

Status Suspended

Clinical Trial Summary

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory or relapsed B-NHL.

Clinical Trial Description

This Phase I study is designed as a pilot trial evaluating the safety and efficacy of CD19/CD20 Dual-CAR-T cell therapy in subjects with refractory and relapsed B-NHL. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD20 Dual-CAR-T cells. Safety and efficacy of CD19/CD20 Dual-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19/CD20 Dual-CAR-T cells therapy in patients with refractory and relapsed B-NHL. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04697290
Study type	Interventional
Source	Beijing Tsinghua Chang Gung Hospital
Contact
Status	Suspended
Phase	Early Phase 1
Start date	March 10, 2022
Completion date	June 10, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00588094` - Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL	Phase 2
Not yet recruiting	`NCT05091541` - A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Recruiting	`NCT03639181` - Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)	Phase 2
Recruiting	`NCT06104553` - A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma	Phase 1/Phase 2
Terminated	`NCT01352312` - Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma	Phase 1
Not yet recruiting	`NCT05771883` - A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide	Phase 1/Phase 2
Not yet recruiting	`NCT06314828` - A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL	Phase 1
Enrolling by invitation	`NCT05332054` - Long-Term Follow-up Study
Completed	`NCT02564744` - Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL	Phase 2
Recruiting	`NCT05453669` - Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL	Phase 1
Recruiting	`NCT05190068` - HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	Phase 1
Suspended	`NCT04746131` - Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)	Phase 1
Active, not recruiting	`NCT00927797` - Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)	Phase 2
Recruiting	`NCT05436223` - Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma	Phase 2
Completed	`NCT00457782` - A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma	Phase 1
Not yet recruiting	`NCT03105596` - Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)	Phase 2